Clinical Trial Update: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis [Phase 2]

View source ↗

Summary

Phase 2 study update of BAY59-7939 (rivaroxaban), an oral direct Factor Xa inhibitor, in patients with acute symptomatic deep-vein thrombosis; the trial status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Venous Thromboembolism

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 2 | Status: COMPLETED